Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL)

Status: Open to Accrual

Learn more:

• clinicaltrials.gov: #NCT04069273
• See news release

Study Contact: studies@hoosiercancer.org; (317) 921-2050.